• 1
    Murray CJL, Evans DB, Acharya A, Baltussen RMPM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000; 9: 235-251.
  • 2
    Hunink MG, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge, MA: Cambridge University Press; 2001.
  • 3
    Leung GM, Wong IOL, Chan WS, Choi S, Lo SV; on behalf of the Health Care Financing Study Group. The ecology of health care in Hong Kong. Soc Sci Med. 2005; 61: 577-590.
  • 4
    Hospital Authority. HA Drug Formulary (November 10, 2008). Available from: [Accessed November 2008.]
  • 5
    Punglia RS, Saito AM, Neville BA, Earle CC, Weeks JC. Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis [serial online]. BMJ. 2010; 340: c845.
  • 6
    Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003; 21: 555-563.
  • 7
    Wong IOL, Kuntz KM, Cowling BJ, Lam CLK, Leung GM. Cost-effectiveness of mammography screening for Chinese women. Cancer. 2007; 110: 885-895.
  • 8
    Yau TK, Lau Y, Kong J, et al. Breast conservation treatment in Hong Kong—early results of 203 patients: retrospective study. Hong Kong Med J. 2002; 8: 322-328.
  • 9
    Lee AWM. Radiation therapy in Hong Kong: heritage and current status. Int J Radiat Oncol Biol Phys. 1997; 37: 131-136.
  • 10
    Hughes SL, Weaver FM, Giobbie-Hurder A, et al. Effectiveness of team-managed home-based primary care. A randomized multicenter trial. JAMA. 2000; 284: 2877-2885.
  • 11
    Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009; 7: 1-9.
  • 12
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 3302-3317.
  • 13
    Lubitz JD, Riley GF. Trends in Medicare payments in the last year of life. N Engl J Med. 1993; 328: 1092-1096.
  • 14
    Lubitz J, Beebe J, Baker C. Longevity and Medicare expenditures. N Engl J Med. 1995; 332: 999-1003.
  • 15
    Hong Kong Breast Cancer Registry. Breast Cancer Facts in Hong Kong 2008 Report. Hong Kong, China: Hong Kong Breast Cancer Foundation; 2009.
  • 16
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
  • 17
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science. 1987; 235: 177-182.
  • 18
    Hong Kong Cancer Registry. Hong Kong Cancer Registry Data, 2008. Available from: [Accessed October 2011.]
  • 19
    Surveillance, Epidemiology, and End Results (SEER). SEER Program public use CD-ROM Program (1973-2002). Bethesda, MD: National Cancer Institute, Division of Cancer Prevention and Control, Surveillance Program, Cancer Statistics Branch; 2002.
  • 20
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 21
    Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women [serial online]. Cochrane Database Syst Rev. 2009;( 4): CD003370.
  • 22
    Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28: 3784-3796.
  • 23
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010; 11: 1135-1141.
  • 24
    Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010; 21: 2153-2160.
  • 25
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
  • 26
    Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev. 2008; 34: 539-557.
  • 27
    Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000; 95: 89-98.
  • 28
    Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol. 2007; 25( 18S). Abstract 512.
  • 29
    Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12: 236-244.
  • 30
    Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) and with docetaxel, carboplatin and trastuzumab (TCH) in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. Paper presented at: 23rd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX.
  • 31
    Census and Statistics Department, Government of Hong Kong SAR. Hong Kong Annual Digest of Statistics; Hong Kong, China: Government of Hong Kong SAR; 2008.
  • 32
    US Department of Labor, Bureau of Labor Statistics. Consumer Price Index (Medical Care). Available from: [Accessed December 2008.]
  • 33
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER/neu-positive breast cancer. J Clin Oncol. 2007; 25: 634-641.
  • 34
    Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 7811-7819.
  • 35
    Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995; 87: 417-426.
  • 36
    Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004; 13: 437-452.
  • 37
    Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ. 2002; 166: 44-47.
  • 38
    Chung RY, Schooling CM, Cowling BJ, Leung GM. How does socioeconomic development affect risk of mortality? An age-period-cohort analysis from a recently transitioned population in China. Am J Epidemiol. 2010; 171: 345-356.
  • 39
    Woo PPS, Kim JJ, Leung GM. What is the most cost-effective population-based cancer screening program for Chinese Women? J Clin Oncol. 2007; 25: 617-624.
  • 40
    Wong IOL, Cowling BJ, Schooling CM, Leung GM. Age-period-cohort projections of breast cancer incidence in a rapidly transitioning Chinese population. Int J Cancer. 2007; 121: 1556-1563.